相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
Jenny J. Kim et al.
CANCER (2012)
Systemic and Kidney Toxicity of Intraocular Administration of Vascular Endothelial Growth Factor Inhibitors
Gaelle Pelle et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2011)
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction
Sachin Gupta et al.
ANTI-CANCER DRUGS (2011)
Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
P. Oesterlund et al.
BRITISH JOURNAL OF CANCER (2011)
Mechanisms of Antiangiogenic-Induced Arterial Hypertension
Jean-Jacques Mourad et al.
CURRENT HYPERTENSION REPORTS (2011)
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesus Garcia-Donas et al.
LANCET ONCOLOGY (2011)
Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration
Kostas Stylianou et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma
Vincent Launay-Vacher et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2011)
Anti-VEGF antibody treatment accelerates polycystic kidney disease
Shagun Raina et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Reversibility of capillary density after discontinuation of bevacizumab treatment
N. Steeghs et al.
ANNALS OF ONCOLOGY (2010)
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Hassane Izzedine et al.
EUROPEAN JOURNAL OF CANCER (2010)
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Michael L. Maitland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy
Olga Costero et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Biology of Anti-Angiogenic Therapy-Induced Thrombotic Microangiopathy
Vera Eremina et al.
SEMINARS IN NEPHROLOGY (2010)
Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor
B. I. Levy
ANNALS OF ONCOLOGY (2009)
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
P. Bono et al.
ANNALS OF ONCOLOGY (2009)
Hypertension as a surrogate marker for the activity of anti-VEGF agents
O. Mir et al.
ANNALS OF ONCOLOGY (2009)
Management of hypertension in angiogenesis inhibitor-treated patients
H. Izzedine et al.
ANNALS OF ONCOLOGY (2009)
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
A. Ravaud et al.
ANNALS OF ONCOLOGY (2009)
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Darren R. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects
Mariette H. W. Kappers et al.
JOURNAL OF HYPERTENSION (2009)
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
Guillaume Bollee et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
J. -J. Mourad et al.
ANNALS OF ONCOLOGY (2008)
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor
Neeltje Steeghs et al.
CLINICAL CANCER RESEARCH (2008)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
Tejas V. Patel et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Glomerular disease related to anti-VEGF therapy
M. Barry Stokes et al.
KIDNEY INTERNATIONAL (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
VEGF inhibition and renal thrombotic microangiopathy
Vera Eremina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
C. Porta et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
Interstitial nephritis in a patient taking sorafenib
Hassane Izzedine et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
Joachim Drevs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hypertension as a predictive factor of Sunitinib activity
O. Rixe et al.
ANNALS OF ONCOLOGY (2007)
Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors
L. Y. Dirix et al.
ANNALS OF ONCOLOGY (2007)
Thrombotic microangiopathy and anti-VEGF agents
Hassane Izzedine et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
Xiaolei Zhu et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia
Vesna D. Garovic et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Henk. M. W. Verheul et al.
NATURE REVIEWS CANCER (2007)
Hypertension - A disease of the microcirculation?
Francois Feihl et al.
HYPERTENSION (2006)
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
Ferry A. L. M. Eskens et al.
EUROPEAN JOURNAL OF CANCER (2006)
Effect of regular phosphodiesterase type 5 inhibition in hypertension
James J. Oliver et al.
HYPERTENSION (2006)
Mechanisms of hypertension associated with BAY 43-9006
ML Veronese et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria
DH Yu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway
Shin-ichiro Miura et al.
HYPERTENSION RESEARCH (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
AV Chobanian et al.
HYPERTENSION (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Vascular endothelial growth factor in ischemia for vascular angiogenesis
TD Henry et al.
CIRCULATION (2003)
Structural and functional changes of the microcirculation in hypertension: Influence of pharmacological therapy
E Agabiti-Rosei
DRUGS (2003)
Immediate and delayed VEGF-mediated NO synthesis in endothelial cells:: Role of PI3K, PKC and PLC pathways
DS Gélinas et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy:: differing effects of anti-proteinuric therapies
DJ Kelly et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
B Li et al.
HYPERTENSION (2002)
VEGF is an essential molecule for glomerular structuring
Y Kitamoto et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
Inhibition of NO biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension
FN Kiefer et al.
BLOOD PRESSURE (2002)
Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN
DB Donoviel et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Common toxicity criteria: Version 2.0. an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy
A Trotti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
分享论文
